Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data Additional data include new Phase 3 RISE and SHINE analyses demonstrating no...

 Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46 For Subset of Patients Previously Receiving 3rd Generation EGFR-TKI: PFS Hazard Ratio of 0.48 5.6% Treatment Discontinuation of Ivonescimab due to Adverse...

Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate’s second generation ANKET®, for the treatment of relapsed/refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma AstraZeneca to present poster on updated results...

Owkin has unveiled its pipeline of four early-stage de novo drug discovery programs and one patent-protected in-licensed drug asset, bringing its world-class data access and AI to the forefront of drug discovery and development Using its proprietary AI engines for...

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization China NMPA approval based on comprehensive clinical data demonstrating robust activity of SUL-DUR against carbapenem-resistant bacterial strains In China, it...

- 70% of Patients Receiving Seladelpar 10mg Achieved the Clinically Meaningful Composite Endpoint and 37% Achieved ALP Normalization at 12 Months - - Reduction in Patient-Reported Pruritus (Itching) was Rapid and Durable in Patients with Moderate to Severe Symptoms - -...

Five-year partnership marks the next phase of their long-standing collaboration to drive the automaker’s transformation for a good and responsible business More than 18,000 users globally will utilize virtual twins to increase the efficiency of vehicle engineering and digital manufacturing,...

First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024 Progression of Sanofi-developed NK Cell Engager SAR443579/IPH6101 to Phase 2 in blood cancers Five ASCO Annual Meeting 2024 abstracts: Final TELLOMAK Phase...

Ashley brings over 25 years’ experience in business and strategy development within the biopharmaceutical industry Will spearhead partnering discussions as the company enters the next phase of its growth Appointment is part of a broader expansion of Epsilogen’s team, facilities and...

LOS ANGELES--(BUSINESS WIRE)--Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE) (“Faraday Future”, “FF” or “Company”), a California-based global shared intelligent electric mobility ecosystem company, announced that consultant Werner Wilhelm is assisting the Company as Executive Launch Director, effective immediately. With an...